EGFR Inhibitors: Types, Drugs, EGFR Mutations, Resistance & Lung Cancer Treatment
EGFR inhibitors are targeted cancer therapies that block the epidermal growth factor receptor (EGFR), a signaling protein that can drive cancer-cell growth. They are particularly important in EGFR-mutated non-small cell lung cancer (NSCLC), where specific genetic alterations can make tumors highly dependent on EGFR signaling.
The EGFR treatment landscape has changed substantially over the past decade. Older first-generation drugs such as gefitinib and erlotinib have been joined by second-generation inhibitors such as afatinib and dacomitinib, third-generation drugs such as osimertinib and lazertinib, and antibody-based approaches such as amivantamab.
.png "EGFR Inhibitors")
The most important question is no longer simply whether a tumor is "EGFR positive." The specific EGFR mutation, cancer stage, previous treatment, resistance mechanism, and presence of brain metastases can all influence treatment selection.
What Is EGFR?
EGFR stands for epidermal growth factor receptor. It is a receptor tyrosine kinase located on the surface of cells. When activated, EGFR transmits signals that regulate cell growth, survival, division and other biological processes.In some cancers, EGFR becomes abnormally activated because of a genetic mutation or increased EGFR signaling. This can create a growth advantage for tumor cells.
EGFR inhibitors interfere with this signaling pathway. In cancers that are strongly dependent on a particular EGFR mutation, blocking the altered receptor can produce substantial tumor shrinkage and delay disease progression.
The National Cancer Institute defines an EGFR inhibitor as a substance that blocks EGFR activity. EGFR inhibitors are also commonly called EGFR tyrosine kinase inhibitors (EGFR TKIs).
What Are EGFR Inhibitors?
EGFR inhibitors are a form of precision oncology. Instead of attacking rapidly dividing cells broadly, as conventional chemotherapy does, targeted EGFR therapy is designed to interfere with a molecular abnormality that is helping the cancer grow.
Most EGFR inhibitors used in EGFR-mutated NSCLC are tyrosine kinase inhibitors taken orally. Another important EGFR-directed treatment, amivantamab, is a monoclonal antibody that binds EGFR and MET.
Importantly, an EGFR inhibitor should not automatically be used simply because EGFR protein is present. For many NSCLC patients, treatment selection depends on identifying a specific actionable EGFR gene alteration.
Which EGFR Mutations Matter?
EGFR-mutated NSCLC is genetically heterogeneous. Some EGFR alterations are highly sensitive to established EGFR TKIs, while others respond differently or may require specialized treatment strategies.EGFR exon 19 deletions
Exon 19 deletions are among the most common sensitizing EGFR mutations in NSCLC. They are strongly associated with response to EGFR-targeted therapy.
EGFR exon 21 L858R
The L858R mutation is another major sensitizing EGFR alteration. Exon 19 deletions and exon 21 L858R account for the classic EGFR-mutated NSCLC population targeted by several approved therapies.
EGFR T790M
T790M became one of the best-known acquired resistance mutations after treatment with earlier-generation EGFR TKIs. The development of third-generation EGFR inhibitors, particularly osimertinib, changed the treatment landscape because these drugs were designed to inhibit T790M while retaining activity against common sensitizing EGFR mutations.
EGFR exon 20 insertions
EGFR exon 20 insertion mutations are biologically distinct from exon 19 deletions and L858R. Historically, many conventional EGFR TKIs had relatively limited activity against these alterations.
Modern treatment therefore increasingly depends on identifying the exact EGFR alteration rather than treating all EGFR mutations as one category.
Uncommon EGFR mutations
Other alterations include mutations involving G719X, S768I and L861Q. Some uncommon mutations can respond to EGFR-targeted therapy, but treatment decisions should be based on the specific alteration and the evidence supporting the proposed drug.
Types of EGFR Inhibitors
EGFR-targeted therapies can broadly be divided into several generations and therapeutic approaches.
First-generation EGFR TKIs
- Gefitinib
- Erlotinib
These drugs reversibly inhibit EGFR signaling and demonstrated that molecularly selected EGFR-mutated NSCLC could respond dramatically to targeted therapy.
Second-generation EGFR TKIs
- Afatinib
- Dacomitinib
These drugs irreversibly inhibit EGFR-family signaling and were developed partly to provide broader inhibition of the HER/ErbB receptor family.
Third-generation EGFR TKIs
- Osimertinib (Tagrisso)
- Lazertinib
Third-generation EGFR inhibitors were designed to selectively target mutant EGFR, including the clinically important T790M resistance mutation, while reducing inhibition of normal EGFR compared with earlier drugs.
EGFR-directed antibodies
- Amivantamab
Amivantamab is different from an oral EGFR TKI. It is a bispecific antibody targeting EGFR and MET and has become an important component of treatment for selected EGFR-mutated NSCLC.
Major EGFR Inhibitor Drugs
Gefitinib
Gefitinib is a first-generation EGFR TKI. It can be used in selected EGFR-mutated NSCLC settings, depending on local regulatory approvals and clinical practice.
Erlotinib
Erlotinib is another first-generation EGFR TKI. Like gefitinib, its clinical role has been reduced in many settings by the development of newer-generation agents.
Afatinib
Afatinib is an irreversible ErbB-family inhibitor. In the United States, afatinib is approved for metastatic NSCLC with non-resistant EGFR mutations detected by an FDA-approved test. The FDA approved the first generic versions of afatinib in July 2026.
Dacomitinib
Dacomitinib is an irreversible EGFR-family TKI approved for metastatic NSCLC with specific EGFR mutations. Its use has to be weighed against toxicity and the availability of newer treatment approaches.
Osimertinib
Osimertinib is one of the central drugs in modern EGFR-mutated NSCLC treatment. It is a third-generation EGFR TKI with activity against common activating EGFR mutations and T790M.
Lazertinib
Lazertinib is another third-generation EGFR TKI. In the United States, it is approved in combination with amivantamab for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
Amivantamab
Amivantamab is an EGFR/MET-directed bispecific antibody. Its role has expanded beyond EGFR exon 20 insertion disease and now includes combination strategies for common EGFR-mutated advanced NSCLC.
Osimertinib: A Major EGFR Inhibitor
Osimertinib (Tagrisso) has become a cornerstone of EGFR-targeted therapy because of its potency against common EGFR mutations, activity against T790M, and ability to penetrate the central nervous system.
It is used in multiple treatment settings. FDA approvals include treatment of selected EGFR-mutated advanced NSCLC and adjuvant treatment after surgery for eligible patients with certain EGFR mutations. Osimertinib was also approved with platinum-based chemotherapy for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
The FLAURA 2 study evaluated osimertinib combined with platinum-based chemotherapy versus osimertinib alone in previously untreated advanced EGFR-mutated NSCLC. The FDA approved the combination in February 2024.
Osimertinib therefore illustrates an important development in precision oncology: treatment is increasingly moving from single-agent targeted therapy toward biomarker-selected combination strategies in appropriate patients.
Lazertinib and Amivantamab
The combination of lazertinib + amivantamab represents another evolution of EGFR-targeted treatment.
The FDA approved the combination in August 2024 for first-line treatment of adults with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations.
The approval was supported by the MARIPOSA trial, which compared the combination with osimertinib and other treatment arms. The rationale is to attack EGFR-driven disease through complementary mechanisms and potentially delay the emergence of resistance.
This does not mean that every patient with an EGFR mutation should receive combination therapy. The optimal regimen depends on mutation type, disease burden, comorbidities, toxicity considerations, patient preference and access.
EGFR Exon 20 Insertions: A Different Treatment Problem
EGFR exon 20 insertion mutations deserve separate consideration because they do not behave like the classic exon 19 deletion and L858R mutations.
In March 2024, the FDA approved amivantamab + carboplatin + pemetrexed as first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Amivantamab also received traditional FDA approval for patients with EGFR exon 20 insertion-mutated NSCLC whose disease progressed during or after platinum-based chemotherapy.
This is an important example of why broad statements such as "EGFR-positive lung cancer" can be misleading. The precise mutation determines which targeted therapies are supported by evidence.
What happened to mobocertinib?
Mobocertinib (Exkivity) was developed specifically for EGFR exon 20 insertion-mutated NSCLC. Its accelerated FDA approval was withdrawn in July 2024 after the required confirmatory evidence did not establish the expected clinical benefit.
Mobocertinib should therefore not be presented as a currently FDA-approved standard EGFR exon 20 therapy in the United States.
EGFR Mutation Testing: The Critical First Step
EGFR-targeted treatment should generally be based on appropriate molecular testing rather than assumptions based on age, smoking history, histology or symptoms.
Testing may use tumor tissue, blood-based circulating tumor DNA, or both. Comprehensive next-generation sequencing can identify EGFR alterations alongside other actionable genomic changes such as ALK, ROS1, BRAF, KRAS, MET, RET, NTRK and HER2.
Why tissue and liquid biopsy can complement each other
A blood-based liquid biopsy can sometimes identify an actionable mutation without requiring a new tissue biopsy. However, a negative plasma result does not necessarily exclude an EGFR mutation because circulating tumor DNA may be insufficient for detection.
When clinically appropriate, tissue testing may therefore remain important after a negative or inconclusive liquid biopsy.
What should an EGFR report tell you?
A useful molecular report should identify:
- The exact EGFR mutation.
- The exon involved.
- Whether the alteration is considered activating or actionable.
- Potentially relevant resistance mutations.
- The testing method used.
- The evidence or treatment implications associated with the alteration.
Why Do EGFR Inhibitors Stop Working?
One of the biggest challenges in EGFR-mutated NSCLC is acquired resistance.
Even when an EGFR inhibitor initially produces a dramatic response, cancer cells can evolve under treatment pressure. Resistant clones may already exist at low levels or emerge through new genetic and biological changes.
Common resistance mechanisms
- EGFR-dependent resistance: additional changes occur within the EGFR protein.
- MET amplification: tumor cells increase signaling through the MET pathway.
- HER2 alterations: alternative growth signaling can contribute to resistance.
- Histologic transformation: the tumor can change its biological phenotype.
- Small-cell transformation: some EGFR-mutated tumors transform into a small-cell phenotype.
- Bypass signaling: cancer cells activate alternative pathways that reduce dependence on EGFR.
A 2026 review in Nature Reviews Clinical Oncology emphasizes that resistance to EGFR TKIs remains a major challenge and that tumor evolution can involve multiple, sometimes overlapping mechanisms.
C797S and fourth-generation EGFR inhibitors
The C797S mutation is an important example of resistance after third-generation covalent EGFR inhibitors. Because these drugs rely on interaction with the C797 residue, alteration of this site can prevent effective drug binding.
This has created interest in fourth-generation EGFR inhibitors designed to target resistant EGFR mutations such as C797S. Several investigational agents are being evaluated in clinical trials, but these should not be confused with established FDA-approved standard therapies.
EGFR Inhibitor Side Effects
EGFR inhibitors can be easier to tolerate than traditional chemotherapy for some patients, but they are not side-effect free.
Common EGFR TKI side effects
- Acneiform or papulopustular rash
- Dry skin
- Diarrhea
- Nail inflammation or paronychia
- Mouth sores
- Reduced appetite
- Fatigue
- Changes in liver function tests
Important but less common toxicities
Certain EGFR inhibitors can cause potentially serious complications, including interstitial lung disease/pneumonitis, cardiac effects, liver toxicity, severe skin reactions and ocular complications.
The precise toxicity profile differs substantially between drugs. For example, afatinib commonly causes diarrhea and skin toxicity, while osimertinib has a different adverse-effect profile that includes important cardiac and pulmonary risks.
New or worsening shortness of breath, significant diarrhea, severe skin reactions, palpitations or other concerning symptoms during treatment should be reported promptly to the oncology team.
EGFR Inhibitors and Brain Metastases
Brain metastases are particularly important in EGFR-mutated NSCLC. The central nervous system can act as a sanctuary site where some cancer drugs have limited penetration.
The development of EGFR inhibitors with meaningful central nervous system activity has therefore been a major advance. Osimertinib is particularly important because of its CNS penetration and clinical activity against brain metastases in EGFR-mutated NSCLC.
This is one reason treatment selection cannot be based solely on response rates outside the brain. For patients with CNS disease, clinicians may specifically consider the ability of a targeted therapy to reach intracranial tumors.
EGFR Inhibitors and Combination Therapy
A major direction in EGFR-mutated lung cancer is combining targeted therapies with other treatments to delay resistance and improve disease control.
Examples include:
- EGFR TKI + chemotherapy
- EGFR TKI + EGFR/MET-directed antibody
- EGFR/MET-directed therapy + chemotherapy
- Targeted therapy combinations designed to suppress bypass pathways
- Investigational combinations involving antibody-drug conjugates
- Investigational combinations involving repurposed drugs
However, combination therapy can increase toxicity. The objective is not simply to use more drugs; it is to identify combinations that produce a favorable balance between disease control, survival, quality of life and treatment burden.
The Future of EGFR-Targeted Therapy
The next generation of EGFR research is increasingly focused on resistance prevention, molecular monitoring and mutation-specific treatment.
1. Fourth-generation EGFR inhibitors
Researchers are developing drugs capable of targeting resistant EGFR alterations such as C797S, including tumors containing multiple resistance mutations.
2. Combination strategies
Combining EGFR inhibitors with chemotherapy, MET-directed therapy, antibodies or other targeted agents may delay resistance in selected patients.
3. Circulating tumor DNA
Serial blood-based molecular testing may provide a way to detect emerging resistance before it becomes obvious on conventional imaging. This approach is still evolving and is not a substitute for standard clinical assessment.
4. Molecularly adaptive treatment
The long-term direction of precision oncology is toward treatment that changes as the molecular profile of the tumor changes.
Instead of thinking of cancer as genetically static, clinicians increasingly view advanced cancer as an evolving population of tumor clones. EGFR treatment is one of the clearest examples of this model.
EGFR Inhibitors at a Glance
- Gefitinib: first-generation EGFR TKI; established activity in selected EGFR-mutated NSCLC.
- Erlotinib: first-generation EGFR TKI; historically important in EGFR-mutated NSCLC.
- Afatinib: second-generation irreversible ErbB-family inhibitor.
- Dacomitinib: second-generation irreversible EGFR-family inhibitor.
- Osimertinib: third-generation EGFR TKI with activity against common activating mutations and T790M; major CNS-active EGFR therapy.
- Lazertinib: third-generation EGFR TKI used in combination with amivantamab in an FDA-approved first-line regimen for selected advanced EGFR-mutated NSCLC.
- Amivantamab: EGFR/MET bispecific antibody used in several EGFR-mutated NSCLC settings, including exon 20 insertion disease.
- Mobocertinib: previously approved through the accelerated pathway for EGFR exon 20 insertion NSCLC; U.S. approval was withdrawn in 2024.
- Fourth-generation EGFR inhibitors: investigational agents being developed to overcome resistance such as C797S.
Frequently Asked Questions About EGFR Inhibitors
What is the best EGFR inhibitor?
There is no single best EGFR inhibitor for every patient. For many patients with common EGFR exon 19 deletion or L858R mutations, osimertinib is a major standard treatment option. Other FDA-approved strategies, including lazertinib plus amivantamab, may also be appropriate depending on the clinical situation.
Are EGFR inhibitors chemotherapy?
No. EGFR TKIs are targeted therapies rather than conventional cytotoxic chemotherapy. Some EGFR-targeted regimens, however, combine an EGFR inhibitor with chemotherapy.
Can EGFR inhibitors cure lung cancer?
In advanced NSCLC, EGFR inhibitors are generally used to control disease rather than described as a guaranteed cure. In earlier-stage disease, targeted EGFR therapy can also be used in selected patients after surgery or other definitive treatment to reduce the risk of recurrence.
Related: EGFR Mutation in Lung Cancer: Complete Treatment Decision Guide (2026 Update)What happens if an EGFR inhibitor stops working?
The next step is often to investigate the mechanism of resistance. Depending on the clinical setting, this may involve tissue biopsy, liquid biopsy, repeat molecular profiling, chemotherapy, antibody-based therapy, another targeted therapy, radiation, or enrollment in a clinical trial.
Does EGFR mutation testing matter?
Yes. Molecular testing is fundamental to modern treatment selection for advanced non-squamous NSCLC and other appropriate NSCLC populations. The exact EGFR mutation can determine whether a particular EGFR-targeted treatment is appropriate.
Are EGFR inhibitors used for cancers other than lung cancer?
Yes. EGFR-directed drugs are used in selected other cancers, including certain colorectal and head and neck cancers. However, the relevant biomarker and treatment strategy differ by cancer type. EGFR-mutated NSCLC is the setting in which EGFR TKIs have become particularly transformative.
Is mobocertinib still FDA approved?
No. The FDA lists mobocertinib's accelerated approval for EGFR exon 20 insertion-mutated NSCLC as withdrawn in July 2024.
Are fourth-generation EGFR inhibitors available?
Some fourth-generation EGFR inhibitors are being investigated in clinical trials, particularly for resistance mutations such as C797S. They remain investigational rather than established standard treatments.
Key Takeaways
- EGFR inhibitors are precision cancer therapies that block EGFR-driven signaling.
- EGFR-mutated NSCLC is not one disease. The exact mutation matters.
- Exon 19 deletion and L858R are the classic sensitizing EGFR mutations.
- Osimertinib is a major third-generation EGFR TKI and an important standard treatment.
- Lazertinib + amivantamab is an FDA-approved first-line option for selected advanced EGFR-mutated NSCLC.
- EGFR exon 20 insertion mutations require a different treatment strategy from common EGFR mutations.
- Amivantamab + carboplatin + pemetrexed is an FDA-approved first-line treatment for EGFR exon 20 insertion-mutated advanced NSCLC.
- Resistance is expected in advanced disease and may involve EGFR mutations, MET amplification, histologic transformation or other bypass pathways.
- Repeat molecular testing can be valuable after progression because the biology of the cancer may have changed.
- Fourth-generation EGFR inhibitors are an important research frontier, particularly for difficult resistance mutations such as C797S.
Sources & Further Reading
- National Cancer Institute — EGFR inhibitor and lung cancer treatment information.
- U.S. Food and Drug Administration — EGFR-targeted drug approvals and prescribing information.
- Nature Reviews Clinical Oncology — reviews of EGFR-mutated NSCLC and mechanisms of EGFR TKI resistance.
- FDA clinical trial evidence for osimertinib, lazertinib and amivantamab-based treatment strategies.
Last reviewed: August 2026. Drug approvals and treatment guidelines can change. Always verify the current indication and prescribing information before making treatment decisions.
.png)
Comments
Post a Comment